| 1. |
Tomoki Ushijima, Yoshihisa Tanoue, Hiromichi Sonoda, Meikun Kan-O, Shinichiro Oda, Satoshi Kimura, Toru Hashimoto, Takeo Fujino, Akira Shiose, Potential of the EVAHEART 2 Double-Cuff Tipless Inflow Cannula for Prevention of Thromboembolic Events., ASAIO journal (American Society for Artificial Internal Organs : 1992), 10.1097/MAT.0000000000001672, 68, 10, e168-e171, 2022.10, A 32-year-old man, who had developed fulminant myocarditis leading to asystole, underwent implantation of an EVAHEART 2 left ventricular assist system with a double-cuff tipless inflow cannula and a concurrent Fontan operation. Approximately 2 years after the simultaneous EVAHEART 2 implantation and the Fontan operation, the patient underwent heart transplantation. There was no device-related thromboembolism or pump malfunction under adequate antithrombotic management during the postoperative support period. Computed tomography showed no malposition of the inflow cannula irrespective of the left ventricular chamber size. Macroscopically, the left ventricular cavity of the excised heart revealed a smooth inflow ostium with appropriate intimal proliferation and without pannus or wedge thrombus formation. These findings suggest the utility of the double-cuff tipless inflow cannula for long-term clinical applications, which may lead to favorable outcomes during long-term patient management. The double-cuff tipless inflow cannula, which does not protrude into the left ventricular cavity, potentially contributes to the prevention of suction events and the collision of the inflow cannula with the interventricular septum and left ventricular free wall. Further investigation is required to confirm the role of the unique EVAHEART 2 inflow cannula in reducing thromboembolic events.. |
| 2. |
Minoru Ono, Osamu Yamaguchi, Tomohito Ohtani, Koichiro Kinugawa, Yoshikatsu Saiki, Yoshiki Sawa, Akira Shiose, Hiroyuki Tsutsui, Norihide Fukushima, Goro Matsumiya, Masanobu Yanase, Kenji Yamazaki, Kazuhiro Yamamoto, Masatoshi Akiyama, Teruhiko Imamura, Kiyotaka Iwasaki, Miyoko Endo, Yoshihiko Ohnishi, Takahiro Okumura, Koichi Kashiwa, Osamu Kinoshita, Kaori Kubota, Osamu Seguchi, Koichi Toda, Hiroshi Nishioka, Tomohiro Nishinaka, Takashi Nishimura, Toru Hashimoto, Masaru Hatano, Haruhiko Higashi, Taiki Higo, Takeo Fujino, Yumiko Hori, Toru Miyoshi, Motoharu Yamanaka, Takayuki Ohno, Takeshi Kimura, Shunei Kyo, Yasushi Sakata, Takeshi Nakatani, JCS/JSCVS/JATS/JSVS 2021 Guideline on Implantable Left Ventricular Assist Device for Patients With Advanced Heart Failure., Circulation journal : official journal of the Japanese Circulation Society, 10.1253/circj.CJ-21-0880, 86, 6, 1024-1058, 2022.05. |
| 3. |
Yuta Nagatomi, Tomomi Ide, Tae Higuchi, Tomoyuki Nezu, Takeo Fujino, Takeshi Tohyama, Takuya Nagata, Taiki Higo, Toru Hashimoto, Shouji Matsushima, Keisuke Shinohara, Tomiko Yokoyama, Aika Eguchi, Ayumi Ogusu, Masataka Ikeda, Yusuke Ishikawa, Fumika Yamashita, Shintaro Kinugawa, Hiroyuki Tsutsui, Home-based cardiac rehabilitation using information and communication technology for heart failure patients with frailty, ESC HEART FAILURE, 10.1002/ehf2.13934, 2022.05, Aims Cardiac rehabilitation (CR) is an evidence-based, secondary preventive strategy that improves mortality and morbidity rates in patients with heart failure (HF). However, the implementation and continuation of CR remains unsatisfactory, particularly for outpatients with physical frailty. This study investigated the efficacy and safety of a comprehensive home-based cardiac rehabilitation (HBCR) programme that combines patient education, exercise guidance, and nutritional guidance using information and communication technology (ICT).Methods and results This study was a single-centre, open-label, randomized, controlled trial. Between April 2020 and November 2020, 30 outpatients with chronic HF (New York Heart Association II-III) and physical frailty were enrolled. The control group (n = 15) continued with standard care, while the HBCR group (n = 15) also received comprehensive, individualized CR, including ICT-based exercise and nutrition guidance using ICT via a Fitbit (R) device for 3 months. The CR team communicated with each patient in HBCR group once a week via the application messaging tool and planned the training frequency and intensity of training individually for the next week according to each patient's symptoms and recorded pulse data during exercise. Dietitians conducted a nutritional assessment and then provided individual nutritional advice using the picture-posting function of the application. The primary outcome was the change in the 6 min walking distance (6MWD). The participants' mean age was 63.7 +/- 10.1 years, 53% were male, and 87% had non-ischaemic heart disease. The observed change in the 6MWD was significantly greater in the HBCR group (52.1 +/- 43.9 m vs. -4.3 +/- 38.8 m; P < 0.001) at a 73% of adherence rate. There was no significant change in adverse events in either group.Conclusions Our comprehensive HBCR programme using ICT for HF patients with physical frailty improved exercise tolerance and improved lower extremity muscle strength in our sample, suggesting management with individualized ICT-based programmes as a safe and effective approach. Considering the increasing number of HF patients with frailty worldwide, our approach provides an efficient method to keep patients engaged in physical activity in their daily life.. |
| 4. |
Mitsukuni Kimura, Toru Hashimoto, Eri Noda, Yusuke Ishikawa, Akihito Ishikita, Takeo Fujino, Shouji Matsushima, Tomomi Ide, Shintaro Kinugawa, Kazuhiro Nagaoka, Tomoki Ushijima, Akira Shiose, Hiroyuki Tsutsui, Fulminant necrotizing eosinophilic myocarditis after COVID-19 vaccination survived with mechanical circulatory support, ESC HEART FAILURE, 10.1002/ehf2.13962, 2022.05, A 69-year-old man was hospitalized for heart failure 7 days after coronavirus disease 2019 (COVID-19) mRNA vaccination. Electrocardiography showed ST-segment elevation and echocardiography demonstrated severe left ventricular dysfunction. Venoarterial extracorporeal membrane oxygenation and Impella 5.0 were instituted because of cardiogenic shock and ventricular fibrillation. Endomyocardial biopsy demonstrated necrotizing eosinophilic myocarditis (NEM). Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) PCR test was negative. He had no infection or history of new drug exposure. NEM was likely related to COVID-19 vaccination. He was administered 10 mg/kg of prednisolone following methylprednisolone pulse treatment (1000 mg/day for 3 days). Left ventricular function recovered and he was weaned from mechanical circulatory support (MCS). Follow-up endomyocardial biopsy showed no inflammatory cell infiltration. This is the first report of biopsy-proven NEM after COVID-19 vaccination survived with MCS and immunosuppression therapy. It is a rare condition but early, accurate diagnosis and early aggressive intervention can rescue patients.. |
| 5. |
Takuya Kanamura, Toru Hashimoto, Akira Shiose, Hiroyuki Tsutsui, Thrombus associated with locked-in atrial fibrillation in recipient remnant left atrium after heart transplantation., European heart journal, 10.1093/eurheartj/ehad008, 44, 18, 1666-1666, 2023.05. |
| 6. |
Nobuyuki Enzan, Shouji Matsushima, Hidetaka Kaku, Takeshi Tohyama, Tomoyuki Nezu, Tae Higuchi, Yuta Nagatomi, Takeo Fujino, Toru Hashimoto, Tomomi Ide, Hiroyuki Tsutsui, Propensity-Matched Study of Early Cardiac Rehabilitation in Patients With Acute Decompensated Heart Failure., Circulation. Heart failure, 10.1161/CIRCHEARTFAILURE.122.010320, 16, 4, e010320, 2023.04, BACKGROUND: The impact of early implementation of cardiac rehabilitation (CR) in heart failure (HF) patients remains to be elucidated. This study sought to determine whether CR during HF hospitalization could improve prognostic outcomes in patients with acute decompensated HF. METHODS: We analyzed patients with HF enrolled in the JROADHF (Japanese Registry of Acute Decompensated Heart Failure) registry, a retrospective, multicenter, nationwide registry of patients hospitalized for acute decompensated HF. Eligible patients were divided into 2 groups according to CR during hospitalization. The primary outcome was a composite of cardiovascular death or rehospitalization due to cardiovascular event after discharge. The secondary outcomes were cardiovascular death and cardiovascular event rehospitalization. RESULTS: Out of 10 473 eligible patients, 3210 patients underwent CR. Propensity score matching yielded 2804 pairs. Mean age was 77±12 years and 3127 (55.8%) were male. During a mean follow-up of 2.8 years, the CR group had lower incidence rates of the composite outcome (291 versus 327 events per 1000 patient-years; rate ratio, 0.890 [95% CI, 0.830-0.954]; P=0.001) and rehospitalization due to cardiovascular event (262 versus 295 events per 1000 patient-years; rate ratio, 0.888 [95% CI, 0.825-0.956]; P=0.002) than the no CR group. In-hospital CR was associated with an improvement in Barthel index for activities of daily living (P=0.002). Patients with very low Barthel index at admission were benefited by CR in comparison with patients with independent Barthel index (very low; hazard ratio, 0.834 [95% CI, 0.742-0.938]: independent; hazard ratio, 0.985 [95% CI, 0.891-1.088]; P for interaction=0.035). CONCLUSIONS: CR implementation during hospitalization was associated with better long-term outcomes in patients with acute decompensated HF. These data support the need for a randomized, controlled, adequately powered trial to definitively test the role of early physical rehabilitation in hospitalized patients with HF.. |
| 7. |
Yoshitomo Tsutsui, Shouji Matsushima, Nobuyuki Enzan, Eri Noda, Keisuke Shinohara, Toru Hashimoto, Tomomi Ide, Shintaro Kinugawa, Hiroyuki Tsutsui, Nationwide Temporal Trends in Clinical Characteristics and Treatment of Dilated Cardiomyopathy From 2003 to 2013 in Japan - A Report From Clinical Personal Records., Circulation journal : official journal of the Japanese Circulation Society, 10.1253/circj.CJ-22-0554, 87, 4, 500-507, 2023.02, BACKGROUND: Little is known about nationwide temporal trends in the clinical characteristics and treatment of dilated cardiomyopathy (DCM) in Japan.Methods and Results: We collected data regarding demographics, echocardiography, and treatment of DCM between 2003 to 2013 from Clinical Personal Records, a national registry organized by the Japanese Ministry of Health, Labour, and Welfare. Among the 40,794 DCM patients screened, 27,702 with left ventricular ejection fraction (LVEF) <50% and age ≥18 years were enrolled in this study and divided into 3 groups according to registration year: Group 1, 2003-2005 (10,006 patients); Group 2, 2006-2010 (11,252 patients); and Group 3, 2011-2013 (6,444 patients). Over time, there were decreases in age at registration (mean [±SD] 58.6±13.0 vs. 56.8±13.8 vs. 56.2±13.8 years; P<0.001) and LVEF (33.5±10.0% vs. 31.1±9.9% vs. 29.2± 9.7%; P<0.001), and an increase in patients with New York Heart Association Class III-IV (28.2% vs. 35.2% vs. 41.0%; P<0.001). The use of β-blockers (59.1% vs. 79.3% vs. 87.8%; P<0.001) and mineralocorticoid receptor antagonists (30.6% vs. 35.8% vs. 39.7%; P<0.001) increased over time. In multivariate analysis, male sex, systolic blood pressure, chronic kidney disease, hemoglobin, and registration year were positively associated, whereas age and LVEF were negatively associated, with β-blocker prescription. CONCLUSIONS: Although the clinical characteristics of DCM changed, the implementation of optimal medical therapy for DCM increased from 2003 to 2013 in Japan.. |
| 8. |
Daisuke Yoshida, Toru Hashimoto, Masato Katsuki, Akihito Ishikita, Yusuke Ishikawa, Takeo Fujino, Keisuke Shinohara, Shouji Matsushima, Shintaro Kinugawa, Yasuhiro Nakano, Shunsuke Katsuki, Tetsuya Matoba, Shunji Hayashidani, Hiroyuki Tsutsui, Histologic Diagnosis of Coronary Amyloidosis Using Percutaneous Transluminal Directional Atherectomy., CJC open, 10.1016/j.cjco.2022.11.009, 5, 1, 99-102, 2023.01. |
| 9. |
Tomoki Ushijima, Yoshihisa Tanoue, Hiromichi Sonoda, Meikun Kan-o, Shinichiro Oda, Satoshi Kimura, Toru Hashimoto, Takeo Fujino, Akira Shiose., Potential of the EVAHEART 2 Double-Cuff Tipless Inflow Cannula for Prevention of Thromboembolic Events., ASAIO J, doi: 10.1097/MAT.0000000000001672., 2022.05. |
| 10. |
Toru Hashimoto, Kazuhiro Kamada, Shouji Matsushima, Taiki Higo, Akira Shiose, Hiroyuki Tsutsui, Regression of Electrocardiographic Left Ventricular Hypertrophy and Strain Pattern Using Pharmacotherapy in a Patient with Dilated Cardiomyopathy, CJC Open, 10.1016/j.cjco.2020.11.009, 3, 3, 387-389, 2021.05. |
| 11. |
Masato Katsuki, Toru Hashimoto*, Tomoki Ushijima, Akira Shiose, Minimized Myocardial Infarction Despite Left Main Coronary Artery Thrombotic Occlusion in a Patient with Left Ventricular Assist Device, European Heart Journal Case Reports, 10.1093/ehjcr/ytab065, 5, 3, 2021.05. |
| 12. |
Takashi Kai, Yoshiyasu Ono, Shouji Matsushima, Keisuke Shinohara, Ryosuke Nakashima, Takuro Kawahara, Masato Katsuki, Takeo Fujino, Toru Hashimoto, Taiki Higo, Hiroyuki Tsutsui, Undiagnosed cardiac sarcoidosis causing refractory heart failure after acute myocardial infarction due to thromboembolism, International Heart Journal, 10.1536/ihj.20-586., 62, 2, 437-440, 2021.03. |
| 13. |
Tasuku Sato, Toru Hashimoto*, Yusuke Ishikawa, Takeo Fujino, Ichiro Sakamoto, Taiki Higo, Akira Shiose, Hiroyuki Tsutsui, Bidirectional Dynamic Change in Shunt Flow across Small Ventricular Septal Defect in a Patient with Left Ventricular Assist Device, CJC Open, 10.1016/j.cjco.2021.03.004, 2021.03. |
| 14. |
Yoshiyasu Ono, Toru Hashimoto*, Kazuo Sakamoto, Shouji Matsushima, Taiki Higo, Hiromichi Sonoda, Yasue Kimura, Masaki Mori, Akira Shiose, Hiroyuki Tsutsui, Effusive-Constrictive Pericarditis Secondary to Pneumopericardium Associated with Gastropericardial Fistula, ESC Heart Failure, 10.1002/ehf2.13135, 8, 1, 778-781, 2021.02, A 66-year-old man with a history of gastric pull-up reconstruction for oesophageal cancer was hospitalized because of prolonged chest pain. Chest X-ray demonstrated pneumopericardium. Computed tomography revealed ulceration and abscess in the gastric conduit adjacent to the heart, suggesting gastropericardial fistula. As the patient did not show tamponade physiology, he was conservatively treated with antibiotics. The pneumopericardium diminished; however, he developed effusive-constrictive pericarditis with overt heart failure symptoms. Because pericardiocentesis failed to relieve the symptoms, pericardiectomy was performed. Intraoperative exploration revealed remarkably thickened pericardium and epicardium constituting multiple layers with purulent effusion. Epicardiectomy as well as pericardiectomy were required to achieve the effective reduction of central venous pressure. Perforation of the gastric conduit into the pericardial cavity was identified and repaired. Histopathology demonstrated thickened pericardium composed of hyalinized stroma, collagenous bundles, and infiltration of inflammatory cells. Streptococcus anginosus and Candida tropicalis were identified by culture of the resected tissue.. |
| 15. |
Soichiro Kashihara, Kisho Ohtani, Tasuku Sato, Akiko Nishizaki, Yoko Shojima, Yuko Deguchi, Takeo Fujino, Toru Hashimoto, Taiki Higo, Hiroyuki Tsutsui, A rare manifestation of right ventricular dysfunction in an adult patient with mucolipidosis type III α/β, Canadian Journal of Cardiology, 10.1016/j.cjca.2020.07.239, 36, 1978.e1-1978.e3, 2020.12. |
| 16. |
Kazuhiro Kamada, Toru Hashimoto*, Akira Shiose, Hiroyuki Tsutsui, Open and Closed Valve Commissural Fusion after Biventricular Assist Device Implantation, European Heart Journal Case Reports, 10.1093/ehjcr/ytaa406., 4, 6, 1-2, 2020.12. |
| 17. |
Ryo Miyake, Kisho Ohtani, Toru Hashimoto, Ryoko Yada, Yoko Shojima, Shunji Hayashidani, Taiki Higo, Hiroyuki Tsutsui., Takotsubo syndrome in a heart transplanted recipient with poor cardiac sympathetic reinnervation., ESC Heart Fail., 7, 1145-1149, ESC Heart Fail. 2020;7:1145-1149., 2020.06. |
| 18. |
Yoshihiko Kodama, Ayako Kuraoka, Yuichi Ishikawa, Makoto Nakamura, Hiroya Ushinohama, Koichi Sagawa, Shintaro Umemoto, Toru Hashimoto, Ichiro Sakamoto, Kisho Ohtani, Tomomi Ide, Hiroyuki Tsutsui, Shiro Ishikaw, The outcome of patients with functional single ventricular heart after pacemaker implantation - what makes it poor and what can we do?, Heart Rhythm, 10.1016/j.hrthm.2019.06.019, 16, 6, 1870-1874, Heart Rhythm. 2019;16:1870-1874., 2019.12, BACKGROUND Pacemaker implantation in patients with single ventricle is associated with poor outcomes.OBJECTIVE The purpose of this study was to determine the reasons for the poor outcomes of pacemaker implantation.METHODS We performed a retrospective chart review of patients with single ventricle who had undergone permanent pacemaker implantation. Patients were categorized into 3 groups based on the site of pacing and the proportion of ventricular pacing (VP) as follows: (1) atrial pacing group with atrial pacing only (n = 11); (2) low VP group with low daily VP proportion (<50%; n = 12); and (3) high VP group with high daily VP proportion (>= 50%; n = 15). Pacing leads were placed at the epicardium in all patients.RESULTS No patients in the atrial pacing or low VP groups died, whereas the survival rate in the high VP group was 58.9% and 39.3% at 10 and 20 years, respectively, after pacemaker implantation. Among the post-Fontan patients, plasma brain natriuretic peptide (BNP) levels significantly increased with the proportion of VP: 11.7, 20.3, and 28.4 pg/mL in the atrial pacing, low VP, and high VP groups, respectively (P = 0.04). In the high VP group, the plasma BNP level was significantly lower in patients with an apical pacing lead than in those with a nonapical pacing lead (27.0 pg/mL vs 82.8 pg/mL, respectively; P = .03).CONCLUSION A higher proportion of VP was associated with poor outcome and higher plasma BNP levels, probably due to ventricular dyssynchrony. In epicardial ventricular pacing, apical pacing is better to avoid the increase in ventricular stress and plasma BNP level.. |
| 19. |
Toru Hashimoto, Grace E. Kim, Richard S. Tunin, Tolulope Adesiyun, Steven Hsu, Ryo Nakagawa, Guangshuo Zhu, Jennifer J. O'Brien, Joseph P. Hendrick, Robert E. Davis, Wei Yao, David Beard, Helen R. Hoxie, Lawrence P. Wennogle, Dong I. Lee, David A. Kass, Acute enhancement of cardiac function by phosphodiesterase type 1 inhibition translational study in the dog and rabbit, Circulation, 10.1161/CIRCULATIONAHA.117.030490, 138, 18, 1974-1987, 2018.01. |
| 20. |
Toru Hashimoto, David A. Kass, Stressed hearts inflame the body (in a good way), Proceedings of the National Academy of Sciences of the United States of America, 10.1073/pnas.1507821112, 112, 23, 7113-7114, 2015.06. |
| 21. |
Toru Hashimoto, Vidhya Sivakumaran, Ricardo Carnicer, Guangshuo Zhu, Virginia S. Hahn, Djahida Bedja, Alice Recalde, Drew Duglan, Keith M. Channon, Barbara Casadei, David A. Kass, Tetrahydrobiopterin protects against hypertrophic heart disease independent of myocardial nitric oxide synthase coupling, Journal of the American Heart Association, 10.1161/JAHA.116.003208, 5, 3, 2015.01. |
| 22. |
Toru Hashimoto, Yuuki Okamatsu, Yohei Hyakuna, Yasuhiro Sedutsu, Kenji Miyata, Hideki Origuchi, Masahiro Mohri, Hideo Yamamoto, Perianeurysmal emphysema: Clostridium septicum-Infected Aortic Aneurysm., Circulation, 10.1161/CIRCULATIONAHA.114.009337, 129, 1900-1901, 2014.05. |
| 23. |
Toru Hashimoto, Toshihiro Ichiki, Aya Watanabe, Eva Hurt-Camejo, Erik Michaëlsson, Jiro Ikeda, Eriko Inoue, Hirohide Matsuura, Tomotake Tokunou, Shiro Kitamoto, Kenji Sunagawa, Stimulation of α7 nicotinic acetylcholine receptor by AR-R17779 suppresses atherosclerosis and aortic aneurysm formation in apolipoprotein E-deficient mice, Vascular Pharmacology, 10.1016/j.vph.2014.03.006, 61, 2-3, 49-55, 2014.01. |
| 24. |
Hirohide Matsuura, Toshihiro Ichiki, Eriko Inoue, Masatoshi Nomura, Ryohei Miyazaki, Toru Hashimoto, Jiro Ikeda, Ryoichi Takayanagi, Guo Hua Fong, Kenji Sunagawa, Prolyl hydroxylase domain protein 2 plays a critical role in diet-induced obesity and glucose intolerance, Circulation, 10.1161/CIRCULATIONAHA.113.001742, 127, 21, 2078-2087, 2013.05. |
| 25. |
Ryohei Miyazaki, Toshihiro Ichiki, Toru Hashimoto, Jiro Ikeda, Aya Kamiharaguchi, Eriko Narabayashi, Hirohide Matsuura, Kotaro Takeda, Kenji Sunagawa, Acetylcholinesterase inhibitors attenuate angiogenesis, Clinical Science, 10.1042/CS20110633, 123, 4, 241-249, 2012.08. |
| 26. |
Toshihiro Ichiki, Ryohei Miyazaki, Aya Kamiharaguchi, Toru Hashimoto, Hirohide Matsuura, Shiro Kitamoto, Tomotake Tokunou, Kenji Sunagawa, Resveratrol attenuates angiotensin II-induced senescence of vascular smooth muscle cells, Regulatory Peptides, 10.1016/j.regpep.2012.04.005, 177, 1-3, 35-39, 2012.08. |
| 27. |
Eriko Inoue, Toshihiro Ichiki, Kotaro Takeda, Hirohide Matsuura, Toru Hashimoto, Jiro Ikeda, Aya Kamiharaguchi, Kenji Sunagawa, Beraprost sodium, a stable prostacyclin analogue, improves insulin resistance in high-fat diet-induced obese mice, Journal of Endocrinology, 10.1530/JOE-12-0014, 213, 3, 285-291, 2012.06. |
| 28. |
Hashimoto Toru, Ichiki Toshihiro, Ikeda Jiro, Narabayashi Eriko, Matsuura Hirohide, Miyazaki Ryohei, Inanaga Keita, Takeda Kotaro, Sunagawa Kenji, Inhibition of MDM2 attenuates neointimal hyperplasia via suppression of vascular proliferation and inflammation, Cardiovascular Research, 10.1093/cvr/cvr108, 91, 4, 711-719, 2011.09. |
| 29. |
Hirohide Matsuura, Toshihiro Ichiki, Jiro Ikeda, Kotaro Takeda, Ryohei Miyazaki, Toru Hashimoto, Eriko Narabayashi, Shiro Kitamoto, Tomotake Tokunou, Kenji Sunagawa, Inhibition of prolyl hydroxylase domain-containing protein downregulates vascular angiotensin II type 1 receptor, Hypertension, 10.1161/HYPERTENSIONAHA.110.167106, 58, 3, 386-393, 2011.09. |
| 30. |
Inanaga Keita, Ichiki Toshihiro, Miyazaki Ryohei, Takeda Kotaro, Hashimoto Toru, Matsuura Hirohide, Sunagawa Kenji, Acetylcholinesterase inhibitors attenuate atherogenesis in apolipoprotein E-knockout mice, Atherosclerosis, 10.1016/j.atherosclerosis.2010.07.027, 213, 1, 52-58, 2010.11. |
| 31. |
Kotaro Takeda, Toshihiro Ichiki, Eriko Narabayashi, Keita Inanaga, Ryohei Miyazaki, Toru Hashimoto, Hirohide Matsuura, Jiro Ikeda, Toshio Miyata, Kenji Sunagawa, Inhibition of prolyl hydroxylase domain-containing protein suppressed lipopolysaccharide-induced TNF-α expression, Arteriosclerosis, thrombosis, and vascular biology, 10.1161/ATVBAHA.109.196071, 29, 12, 2132-2137, 2009.12. |
| 32. |
GAN Lu, MATSUURA Hirohide, ICHIKI Toshihiro, YIN Xinhua, MIYAZAKI Ryohei, HASHIMOTO Toru, CUI Juan, TAKEDA Kotaro, SUNAGAWA Kenji, Improvement of neovascularization capacity of bone marrow mononuclear cells from diabetic mice by ex vivo pretreatment with resveratrol, Hypertension research : clinical and experimental : official journal of the Japanese Society of Hypertension, 10.1038/hr.2009.67, 32, 7, 542-547, 2009.07. |
| 33. |
INANAGA Keita, ICHIKI Toshihiro, MATSUURA Hirohide, MIYAZAKI Ryohei, HASHIMOTO Toru, TAKEDA Kotaro, SUNAGAWA Kenji, Resveratrol attenuates angiotensin II-induced interleukin-6 expression and perivascular fibrosis, Hypertension research : clinical and experimental : official journal of the Japanese Society of Hypertension, 10.1038/hr.2009.47, 32, 6, 466-471, 2009.06. |
| 34. |
Ryohei Miyazaki, Toshihiro Ichiki, Toru Hashimoto, Keita Inanaga, Ikuyo Imayama, Junichi Sadoshima, Kenji Sunagawa, SIRT1, a longevity gene, downregulates angiotensin II type 1 receptor expression in vascular smooth muscle cells, Arteriosclerosis, thrombosis, and vascular biology, 10.1161/ATVBAHA.108.166991, 28, 7, 1263-1269, 2008.07. |
